Boniva (BioDeep_00000015176)
代谢物信息卡片
Ibandronate sodium
化学式: C9H24NNaO8P2 (359.08748039999995)
中文名称: 伊班膦酸钠
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)[O-].O.[Na+]
InChI: +1
描述信息
C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor
D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGG: C72551
- KEGGdrug: D04486
- PubChem: 23663991
- ChEMBL: CHEMBL3989569
- MeSH: Ibandronic Acid
- CAS: 138926-19-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Pengfei Li, Xiaojian Wu, Ye Li, Jianhua Huang. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Clinical and investigative medicine. Medecine clinique et experimentale.
2022 09; 45(3):E14-22. doi:
10.25011/cim.v45i3.38875. [PMID: 36149052] - Jinyoung Kim, Kyoung Min Kim, Soo Lim, Moo-Il Kang, Ki-Hyun Baek, Yong-Ki Min. Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial.
BMC endocrine disorders.
2022 Apr; 22(1):99. doi:
10.1186/s12902-022-01010-w. [PMID: 35410197] - Tingting Xu, Yingwei Wang, Zan Chen, Hanxiang Liu, Songsong Yang, Guangfu Liu, Yan Zhao, Wenhui Fu, Lin Liu, Ke Xiang, Dengsai Peng, Yue Chen. Preparation, Characterization, and Preliminary Imaging Study of [188Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis.
Contrast media & molecular imaging.
2022; 2022(?):7684076. doi:
10.1155/2022/7684076. [PMID: 35280705] - S Hildebrand, J Cunningham. Is there a role for bisphosphonates in vascular calcification in chronic kidney disease?.
Bone.
2021 01; 142(?):115751. doi:
10.1016/j.bone.2020.115751. [PMID: 33188959] - Andreas Fontalis, Richard Eastell. The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
Bone.
2020 07; 136(?):115336. doi:
10.1016/j.bone.2020.115336. [PMID: 32234415] - W-Y Chiu, C-J Lin, W-S Yang, K-S Tsai, J-Y Reginster. Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2020 Jan; 31(1):193-201. doi:
10.1007/s00198-019-05127-y. [PMID: 31642977] - Jing An, Ye Jiang, Yanfang Lu, Lin Zhang, Meng Xu, Zili Hou. Development and application of a urine drug concentration method for the evaluation of oral absorption of ibandronate in clinical patients.
Bioanalysis.
2019 Jul; 11(14):1337-1345. doi:
10.4155/bio-2018-0223. [PMID: 31392890] - Akira Horikawa, Naohisa Miyakoshi, Michio Hongo, Yuji Kasukawa, Hiroyuki Kodama, Yoichi Shimada. A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis.
Medicine.
2019 Feb; 98(6):e14340. doi:
10.1097/md.0000000000014340. [PMID: 30732159] - Frank-Peter Tillmann, Wolfgang Grotz, Lars Christian Rump, Przemyslaw Pisarski. Impact of monocyte-macrophage inhibition by ibandronate on graft function and survival after kidney transplantation: a single-centre follow-up study over 15 years.
Clinical and experimental nephrology.
2018 Apr; 22(2):474-480. doi:
10.1007/s10157-017-1470-1. [PMID: 28856476] - Sevcihan Gunen Yilmaz, Fatih Yılmaz. Bisphosphonate-related osteonecrosis of the jaw in a chronic hemodialysis patient.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.
2018 Jan; 29(1):223-224. doi:
10.4103/1319-2442.225187. [PMID: 29456237] - Naga Yalla. Bad Breaks.
Clinical chemistry.
2018 01; 64(1):47-50. doi:
10.1373/clinchem.2017.279430. [PMID: 29295835] - Knut T Smerud, Anders Åsberg, Håkon Kile, Andreas Pasch, Dag O Dahle, Jens Bollerslev, Kristin Godang, Anders Hartmann. A rapid and sustained improvement of calcification propensity score (serum T50 ) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate.
Clinical transplantation.
2017 Dec; 31(12):. doi:
10.1111/ctr.13131. [PMID: 28972673] - A W Popp, R Senn, I Curkovic, C Senn, H Buffat, P F Popp, K Lippuner. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2017 06; 28(6):1995-2002. doi:
10.1007/s00198-017-3992-5. [PMID: 28299378] - Kichul Shin, Sung-Hwan Park, Won Park, Han Joo Baek, Yun Jong Lee, Seong Wook Kang, Jung-Yoon Choe, Wan-Hee Yoo, Yong-Beom Park, Jung-Soo Song, Seung-Geun Lee, Bin Yoo, Dae-Hyun Yoo, Yeong Wook Song. Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial.
Clinical therapeutics.
2017 Feb; 39(2):268-278.e2. doi:
10.1016/j.clinthera.2017.01.008. [PMID: 28161119] - Jun Zhou, Yuan Liao, Haitao Xie, Ying Liao, Yahua Zeng, Neng Li, Guanghua Sun, Qi Wu, Guijuan Zhou. Effects of combined treatment with ibandronate and pulsed electromagnetic field on ovariectomy-induced osteoporosis in rats.
Bioelectromagnetics.
2017 Jan; 38(1):31-40. doi:
10.1002/bem.22012. [PMID: 27711964] - Ruliang Wang, Shaohua Zhang, Zefei Jiang, Jizheng Tian, Tao Wang, Santai Song. Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer.
Clinical and experimental pharmacology & physiology.
2017 01; 44(1):88-93. doi:
10.1111/1440-1681.12673. [PMID: 27716993] - Tetsuo Nakano, Masao Yamamoto, Junko Hashimoto, Masato Tobinai, Seitaro Yoshida, Toshitaka Nakamura. Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
Journal of bone and mineral metabolism.
2016 Nov; 34(6):678-684. doi:
10.1007/s00774-015-0717-8. [PMID: 26462480] - Mantas Šilkūnas, Rita Saulė, Danutė Batiuškaitė, Gintautas Saulis. The Electroporation as a Tool for Studying the Role of Plasma Membrane in the Mechanism of Cytotoxicity of Bisphosphonates and Menadione.
The Journal of membrane biology.
2016 10; 249(5):611-621. doi:
10.1007/s00232-016-9895-0. [PMID: 27044359] - Kiyohiko Nakai, Masato Tobinai, Junko Hashimoto, Satofumi Iida, Takehiko Kawanishi. The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.
European journal of drug metabolism and pharmacokinetics.
2016 Apr; 41(2):139-47. doi:
10.1007/s13318-014-0242-5. [PMID: 25476995] - F P Tillmann, M Schmitz, M Jäger, R Krauspe, L C Rump. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
International urology and nephrology.
2016 Feb; 48(2):279-86. doi:
10.1007/s11255-015-1133-7. [PMID: 26498632] - Michał Stuss, Ewa Sewerynek, Iwona Król, Wioletta Stępień-Kłos, Sławomir Jędrzejczyk. Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Endokrynologia Polska.
2016; 67(2):174-84. doi:
10.5603/ep.a2016.0014. [PMID: 26884284] - Zeren Ma, Yong Li, Ming Zhou, Kedi Huang, Hejun Hu, Xiaoping Liu, Xiaosheng Xu. Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.
PloS one.
2016; 11(3):e0150203. doi:
10.1371/journal.pone.0150203. [PMID: 26930292] - R Bergner, B Siegrist, N Gretz, G Pohlmeyer-Esch, B Kränzlin. Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.
Pharmacological research.
2015 Sep; 99(?):16-22. doi:
10.1016/j.phrs.2015.04.016. [PMID: 25976681] - Ana Sánchez-Escuredo, David Fuster, Domenico Rubello, Africa Muxí, Ana Ramos, Francisco Campos, Maria Cristina Marzola, Gary J Cook, Andrés Tapias, José-Vicente Torregrosa. Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients.
Nuclear medicine communications.
2015 Aug; 36(8):815-8. doi:
10.1097/mnm.0000000000000316. [PMID: 25856225] - N B Srividhya, Nilanchali Singh, Neerja Goel, J K Gambhir, Vinita Rathi, Shalini Rajaram. Comparison of antiresorptive effect of hormone therapy and ibandronate in postmenopausal osteoporotic women by assessing type I collagen C-telopeptide levels.
Post reproductive health.
2015 Jun; 21(2):48-55. doi:
10.1177/2053369115574613. [PMID: 25792627] - Iain R Macpherson, Caroline Bray, Carol Hopkins, Rosemary A Hannon, Liz-Anne Lewsley, Diana M Ritchie, Peter Canney. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
Clinical breast cancer.
2015 Apr; 15(2):117-27. doi:
10.1016/j.clbc.2014.09.009. [PMID: 25454689] - Tatjana I Gabbert, Bodo Hoffmeister, Dieter Felsenberg. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Journal of cancer research and clinical oncology.
2015 Apr; 141(4):749-58. doi:
10.1007/s00432-014-1853-6. [PMID: 25319961] - S Tariq, S Tariq, S S Alam, M Baig. Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2015 Mar; 26(3):1187-92. doi:
10.1007/s00198-014-2909-9. [PMID: 25274281] - Dörte W Luedders, Jürgen Steinhoff, Marc Thill, Achim Rody, Michael K Bohlmann. Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
Anticancer research.
2015 Mar; 35(3):1797-802. doi:
NULL. [PMID: 25750345] - Kiyohiko Nakai, Satofumi Iida, Masato Tobinai, Junko Hashimoto, Takehiko Kawanishi. Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment.
Clinical pharmacokinetics.
2015 Mar; 54(3):295-304. doi:
10.1007/s40262-014-0206-6. [PMID: 25403846] - Ling-Xiao Chen, Zhi-Rui Zhou, Yu-Lin Li, Guang-Zhi Ning, Tian-Song Zhang, Di Zhang, Shi-Qing Feng. Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
PloS one.
2015; 10(5):e0128032. doi:
10.1371/journal.pone.0128032. [PMID: 26010450] - J P Brown, C Roux, P R Ho, M A Bolognese, J Hall, H G Bone, S Bonnick, J P van den Bergh, I Ferreira, P Dakin, R B Wagman, C Recknor. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2014 Jul; 25(7):1953-61. doi:
10.1007/s00198-014-2692-7. [PMID: 24676847] - Stefan Teufel, Bettina Grötsch, Julia Luther, Anja Derer, Thorsten Schinke, Michael Amling, Georg Schett, Dirk Mielenz, Jean-Pierre David. Inhibition of bone remodeling in young mice by bisphosphonate displaces the plasma cell niche into the spleen.
Journal of immunology (Baltimore, Md. : 1950).
2014 Jul; 193(1):223-33. doi:
10.4049/jimmunol.1302713. [PMID: 24899506] - Augusto Filipe, Pedro Pedroso, Susana Almeida, Rita Neves, Sylvie Boudreault. Bioequivalence study of two formulations of ibandronic acid 150-mg film-coated tablets in healthy volunteers under fasting conditions: a randomized, open-label, three-way, reference-replicated crossover study.
Drugs in R&D.
2014 Jun; 14(2):105-12. doi:
10.1007/s40268-014-0044-x. [PMID: 24756462] - S Gonnelli, C Caffarelli, L Tanzilli, C Pondrelli, B Lucani, B M Franci, R Nuti. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women.
Bone.
2014 Apr; 61(?):27-32. doi:
10.1016/j.bone.2013.12.017. [PMID: 24389416] - Ji-Young Jeon, Sun Young Lee, Yong-Jin Im, Eun-Young Kim, Yunjeong Kim, Tae Sun Park, Soo-Wan Chae, Jae Won Lee, Hun Jun, Tae Won Lee, Min-Gul Kim. Comparison of the pharmacokinetics, safety, and tolerability of vitamin D3 in DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet) and as monotherapy (24,000 iu) in healthy male Korean adults.
Clinical therapeutics.
2014 Jan; 36(1):48-57. doi:
10.1016/j.clinthera.2013.12.001. [PMID: 24378207] - R Bergner, B Siegrist, B Kränzlin, N Gretz, H Faust, T Pfister. Determination of renal tissue ibandronate levels in rats with normal and mildly impaired renal function.
Journal of pharmacological and toxicological methods.
2013 Sep; 68(2):225-230. doi:
10.1016/j.vascn.2012.12.001. [PMID: 23261819] - Panagiotis Anagnostis, Timoleon-Achilleas Vyzantiadis, Maria Charizopoulou, Fotini Adamidou, Spyridon Karras, Dimitrios G Goulis, Asterios Karagiannis, Vasilia Garipidou, Sofia Vakalopoulou. The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.
Thrombosis and haemostasis.
2013 Aug; 110(2):257-63. doi:
10.1160/th13-01-0030. [PMID: 23740140] - Chris Recknor, Edward Czerwinski, Henry G Bone, Sydney L Bonnick, Neil Binkley, Santiago Palacios, Alfred Moffett, Suresh Siddhanti, Irene Ferreira, Prayashi Ghelani, Rachel B Wagman, Jesse W Hall, Michael A Bolognese, Claude-Laurent Benhamou. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.
Obstetrics and gynecology.
2013 Jun; 121(6):1291-1299. doi:
10.1097/aog.0b013e318291718c. [PMID: 23812464] - Michal Stuss, Piotr Rieske, Agnieszka Cegłowska, Wioletta Stêpień-Kłos, Paweł P Liberski, Ewa Brzeziańska, Ewa Sewerynek. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
The Journal of clinical endocrinology and metabolism.
2013 May; 98(5):E1007-11. doi:
10.1210/jc.2012-3885. [PMID: 23543663] - Manish Rauthan, Parmida Ranji, Nataly Aguilera Pradenas, Christophe Pitot, Marc Pilon. The mitochondrial unfolded protein response activator ATFS-1 protects cells from inhibition of the mevalonate pathway.
Proceedings of the National Academy of Sciences of the United States of America.
2013 Apr; 110(15):5981-6. doi:
10.1073/pnas.1218778110. [PMID: 23530189] - Jin Woo Park, Seung Rim Hwang, Ok-Cheol Jeon, Hyun Tae Moon, Youngro Byun. Enhanced oral absorption of ibandronate via complex formation with bile acid derivative.
Journal of pharmaceutical sciences.
2013 Feb; 102(2):341-6. doi:
10.1002/jps.23413. [PMID: 23233267] - K T Smerud, S Dolgos, I C Olsen, A Åsberg, S Sagedal, A V Reisæter, K Midtvedt, P Pfeffer, T Ueland, K Godang, J Bollerslev, A Hartmann. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
2012 Dec; 12(12):3316-25. doi:
10.1111/j.1600-6143.2012.04233.x. [PMID: 22946930] - Sung Jin Bae, Beom-Jun Kim, Kyeong Hye Lim, Seung Hun Lee, Hong Kyu Kim, Ghi Su Kim, Jung-Min Koh. Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Journal of bone and mineral metabolism.
2012 Sep; 30(5):588-95. doi:
10.1007/s00774-012-0361-5. [PMID: 22610063] - D Kaemmerer, B Schmidt, G Lehmann, G Wolf, M Hommann, U Settmacher. Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.
Transplantation proceedings.
2012 Jun; 44(5):1362-7. doi:
10.1016/j.transproceed.2012.01.133. [PMID: 22664016] - José V Torregrosa, Carlos E Durán, Xoana Barros, Miquel Blasco, Marta Arias, Aleix Cases, Josep M Campistol. Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
2012 May; 32(3):329-34. doi:
10.3265/nefrologia.pre2012.jan.11137. [PMID: 22592420] - Yu Chen, Yuxiu Liu, Zhidong Chen, Meilan Chen, Yan Zhu. [Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection].
Se pu = Chinese journal of chromatography.
2012 Apr; 30(4):414-8. doi:
10.3724/sp.j.1123.2011.12070. [PMID: 22799202] - B Bittner, C McIntyre, H Tian, K Tang, N Shah, W Phuapradit, H Ahmed, H Chokshi, M Infeld, N Fotaki, H Ma, A Portron, P Jordan, J Schmidt. Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).
Die Pharmazie.
2012 Mar; 67(3):233-41. doi:
NULL. [PMID: 22530305] - Kadri Altundag, Omer Dizdar, Zeynep Ozsaran, Serdar Ozkok, Pinar Saip, Yesim Eralp, Seref Komurcu, Okan Kuzhan, Mustafa Ozguroglu, Metin Karahoca. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.
Onkologie.
2012; 35(5):254-8. doi:
10.1159/000338369. [PMID: 22868504] - Jelena S Rudic, Vanja Giljaca, Miodrag N Krstic, Goran Bjelakovic, Christian Gluud. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
The Cochrane database of systematic reviews.
2011 Dec; ?(12):CD009144. doi:
10.1002/14651858.cd009144.pub2. [PMID: 22161446] - Concepcion De La Piedra, I Quiroga, M Montero, S Dapia, J R Caeiro, M Rubert, M Diaz-Curiel, F Bauss. Daily or monthly ibandronate prevents or restores deteriorations of bone mass, architecture, biomechanical properties and markers of bone turnover in androgen-deficient aged rats.
The aging male : the official journal of the International Society for the Study of the Aging Male.
2011 Dec; 14(4):220-30. doi:
10.3109/13685538.2010.518176. [PMID: 20937008] - Paul D Miller, Sergio Ragi-Eis, Carlos Mautalen, Francisco Ramirez, Iris Jonkanski. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.
Bone.
2011 Dec; 49(6):1317-22. doi:
10.1016/j.bone.2011.09.035. [PMID: 21945737] - Dhananjay D Marathe, Anshu Marathe, Donald E Mager. Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women.
Biopharmaceutics & drug disposition.
2011 Nov; 32(8):471-81. doi:
10.1002/bdd.770. [PMID: 21953540] - Yu-Shan Huang, Shun-Niang Chen, Chen-Wen Whang. Capillary electrophoresis-electrochemiluminescence detection method for the analysis of ibandronate in drug formulations and human urine.
Electrophoresis.
2011 Aug; 32(16):2155-60. doi:
10.1002/elps.201100202. [PMID: 21793001] - Y Yeh, D Slovik, D Carter, M Clapp, W Churchill, P Reddy. Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline.
Journal of clinical pharmacy and therapeutics.
2011 Jun; 36(3):342-7. doi:
10.1111/j.1365-2710.2010.01186.x. [PMID: 21545613] - Xiao Yang, Yong Hoow Chan, Padmalosini Muthukumaran, Shamal Dasde, Swee-Hin Teoh, Taeyong Lee. Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: a microarchitectural and mechanical study.
Bone.
2011 May; 48(5):1154-63. doi:
10.1016/j.bone.2011.02.007. [PMID: 21334474] - Dick Ho-Kiu Chow, Kwok-Sui Leung, Ling Qin, Andraay Hon-Chi Leung, Wing-Hoi Cheung. Low-magnitude high-frequency vibration (LMHFV) enhances bone remodeling in osteoporotic rat femoral fracture healing.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
2011 May; 29(5):746-52. doi:
10.1002/jor.21303. [PMID: 21437955] - Ryszard Grenda, Elżbieta Karczmarewicz, Jacek Rubik, Halina Matusik, Paweł Płudowski, Małgorzata Kiliszek, Jarosław Piskorski. Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients--a prospective study.
Pediatric transplantation.
2011 Mar; 15(2):205-13. doi:
10.1111/j.1399-3046.2010.01448.x. [PMID: 21199211] - Małgorzata Wegierska, Piotr Ignaczak, Joanna Zalewska, Sławomir Jeka. [Paget's disease: case report].
Annales Academiae Medicae Stetinensis.
2011; 57(3):64-9; discussion 69. doi:
. [PMID: 23383549] - Beate Bittner, Christine McIntyre, Paul Jordan, Johannes Schmidt. Drug-drug interaction study between a novel oral ibandronate formulation and metformin.
Arzneimittel-Forschung.
2011; 61(12):707-13. doi:
10.1055/s-0031-1300591. [PMID: 22282958] - Dagmar-Christiane Fischer, Claudia Jensen, Anja Rahn, Birgit Salewski, Günther Kundt, Geert J Behets, Patrick D'Haese, Dieter Haffner. Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function.
Pediatric nephrology (Berlin, Germany).
2011 Jan; 26(1):111-7. doi:
10.1007/s00467-010-1660-5. [PMID: 20953634] - D J Leeming, D V Larsen, C Zhang, Y Hi, S S Veidal, R H Nielsen, K Henriksen, Q Zheng, V Barkholt, B J Riis, I Byrjalsen, P Qvist, M A Karsdal. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes.
Clinical biochemistry.
2010 Oct; 43(15):1249-56. doi:
10.1016/j.clinbiochem.2010.07.025. [PMID: 20709044] - Ingo J Diel, Andreas H A Kurth, Hans-Bernd Sittig, Harald Meden, Michael Maasberg, Andreas Sandermann, Raoul Bergner. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
2010 Oct; 18(10):1305-12. doi:
10.1007/s00520-009-0749-5. [PMID: 20151162] - Mireya Fernández, Ana M Pino, Paula Figueroa, Juan P Rodríguez. The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate.
Journal of cellular biochemistry.
2010 Sep; 111(1):130-7. doi:
10.1002/jcb.22676. [PMID: 20506157] - Mei Li, Xiao-ping Xing, Zhen-lin Zhang, Jian-li Liu, Zhong-lan Zhang, Dong-gang Liu, Wei-bo Xia, Xun-wu Meng. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
Journal of bone and mineral metabolism.
2010 May; 28(3):299-305. doi:
10.1007/s00774-009-0126-y. [PMID: 19855926] - Marc C Hochberg, Stuart L Silverman, Charles E Barr, Paul D Miller. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
2010 Apr; 13(2):181-9. doi:
10.1016/j.jocd.2010.01.007. [PMID: 20347369] - S Houston, R J Grieve, T Hickish, F Percival, E Hamilton. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Journal of medical economics.
2010 Mar; 13(1):162-7. doi:
10.3111/13696991003640383. [PMID: 20136578] - Roger von Moos, Clemens B Caspar, Rolf Steiner, Rahel Angst, Roman Inauen, Kerstin Schmieding, Beat Thürlimann. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
Onkologie.
2010; 33(8-9):447-50. doi:
10.1159/000317256. [PMID: 20838060] - Rudolf Weide, Hubert Koppler, Lucia Antras, Michael Smith, M P H Eva Chang, Jesse Green, Neil Wintfeld, Maureen P Neary, Mei Sheng Duh. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Journal of cancer research and therapeutics.
2010 Jan; 6(1):31-5. doi:
10.4103/0973-1482.63570. [PMID: 20479544] - Isabela Tarcomnicu, Mihaela Cristina Gheorghe, Luigi Silvestro, Simona Rizea Savu, Irina Boaru, Ariana Tudoroniu. High-throughput HPLC-MS/MS method to determine ibandronate in human plasma for pharmacokinetic applications.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Oct; 877(27):3159-68. doi:
10.1016/j.jchromb.2009.08.007. [PMID: 19700377] - N Binkley, S L Silverman, C Simonelli, N Santiago, J D Kohles, G Dasic, J A Sunyecz. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2009 Sep; 20(9):1595-601. doi:
10.1007/s00198-008-0827-4. [PMID: 19145396] - Annie Wai-Chee Kung, Ichramsjah A Rachman, John M F Adam, Djoko Roeshadi, Tito Torralba, Sandra Navarra, Zayda Gamilla, Arthur Cañete, Miles de la Rosa, KehSung Tsai, Hsiao-Yi Lin, Yung Kuei Soong, Joung-Liang Lan, Horng-Chaung Hsu, Shih-Te Tu, Ruey-Mo Lin, Pongsak Yuktanandana, Thawee Songpatanasilp, Srihatach Ngarmukos, Sugree Soontrapa, Suppasin Soontrapa, Sattaya Rojanasthien, Sirichai Luevitoonvechkij, Taninnit Leerapan, Adelin Albert, Sophie Vanbelle. Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women.
International journal of rheumatic diseases.
2009 Sep; 12(3):216-24. doi:
10.1111/j.1756-185x.2009.01413.x. [PMID: 20374349] - Dirk M Henrich, Martin Hoffmann, Michael Uppenkamp, Raoul Bergner. Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series.
Onkologie.
2009 Sep; 32(8-9):482-6. doi:
10.1159/000226141. [PMID: 19745591] - A Baraniskin, W Schmiegel, Roland Schroers. [Emergencies in hematology and oncology].
Deutsche medizinische Wochenschrift (1946).
2009 Sep; 134(38):1879-88; quiz 1889. doi:
10.1055/s-0029-1237528. [PMID: 19746331] - Ingo J Diel, Rudolf Weide, Hubert Köppler, Lucia Antràs, Michael Smith, Jesse Green, Neil Wintfeld, Maureen Neary, Mei Sheng Duh. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
2009 Jun; 17(6):719-25. doi:
10.1007/s00520-008-0553-7. [PMID: 19089462] - Ronald Emkey, Pierre D Delmas, Michael Bolognese, Joao Lindolfo C Borges, Felicia Cosman, Sergio Ragi-Eis, Christopher Recknor, Cristiano A Zerbini, Colin Neate, Farhad Sedarati, Solomon Epstein. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Clinical therapeutics.
2009 Apr; 31(4):751-61. doi:
10.1016/j.clinthera.2009.04.018. [PMID: 19446148] - Kyriaki Mystakidou, Evangelia Stathopoulou, Efi Parpa, Vassilios Kouloulias, Evangelia Kouskouni, Lambros Vlahos. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.
Journal of cancer research and clinical oncology.
2008 Dec; 134(12):1303-10. doi:
10.1007/s00432-008-0419-x. [PMID: 18504612] - P D Miller, P Ward, T Pfister, C Leigh, J J Body. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.
Clinical and experimental rheumatology.
2008 Nov; 26(6):1125-33. doi:
NULL. [PMID: 19210886] - James E Lester, David Dodwell, Omprakash P Purohit, Sandra A Gutcher, Susan P Ellis, Ruth Thorpe, Janet M Horsman, Janet E Brown, Rosemary A Hannon, Robert E Coleman. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 Oct; 14(19):6336-42. doi:
10.1158/1078-0432.ccr-07-5101. [PMID: 18829518] - A I Sebba, S Broy, J D Kohles, P Weissman. Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naïve population.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
2008 Jul; 11(3):417-23. doi:
10.1016/j.jocd.2008.02.004. [PMID: 18456528] - R von Moos, C B Caspar, B Thürlimann, R Angst, R Inauen, R Greil, B Bergstrom, K Schmieding, M Pecherstorfer. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
Annals of oncology : official journal of the European Society for Medical Oncology.
2008 Jul; 19(7):1266-1270. doi:
10.1093/annonc/mdn038. [PMID: 18334511] - R Bergner, D Henrich, M Hoffmann, H Schmidt-Gayk, T Lenz, M Upperkamp. Treatment of reduced bone density with ibandronate in dialysis patients.
Journal of nephrology.
2008 Jul; 21(4):510-6. doi:
NULL. [PMID: 18651540] - Jean-Yves Reginster, Audrey Neuprez, Olivier Bruyère. Ibandronate in profile: drug characteristics and clinical efficacy.
Expert opinion on drug metabolism & toxicology.
2008 Jul; 4(7):941-51. doi:
10.1517/17425255.4.7.941. [PMID: 18624681] - Anke Lühe, Klaus-Peter Künkele, Monika Haiker, Karen Schad, Christine Zihlmann, Frieder Bauss, Laura Suter, Thomas Pfister. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.
Toxicology in vitro : an international journal published in association with BIBRA.
2008 Jun; 22(4):899-909. doi:
10.1016/j.tiv.2008.01.006. [PMID: 18325729] - John A Eisman, Roberto Civitelli, Silvano Adami, Edward Czerwinski, Chris Recknor, Richard Prince, Jean-Yves Reginster, Mone Zaidi, Dieter Felsenberg, Claire Hughes, Nicole Mairon, Daiva Masanauskaite, David M Reid, Pierre D Delmas, Robert R Recker. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
The Journal of rheumatology.
2008 Mar; 35(3):488-97. doi:
NULL. [PMID: 18260172] - I Byrjalsen, D J Leeming, P Qvist, C Christiansen, M A Karsdal. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2008 Mar; 19(3):339-48. doi:
10.1007/s00198-007-0462-5. [PMID: 17846859] - C G Georges, M Guthoff, M Wehrmann, R Teichmann, E Gröne, F Artunc, T Risler, B Friedrich, K Müssig. [Hypercalcaemic crisis and acute renal failure due to primary hyperparathyroidism].
Deutsche medizinische Wochenschrift (1946).
2008; 133(Suppl 0):F3. doi:
10.1055/s-0028-1082823. [PMID: 19065508] - Timo K Joensuu. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
Urologia internationalis.
2008; 80(4):448-50. doi:
10.1159/000132707. [PMID: 18587260] - Frederick H Wezeman, Dainius Juknelis, Ryan Himes, John J Callaci. Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats.
Bone.
2007 Oct; 41(4):639-45. doi:
10.1016/j.bone.2007.06.002. [PMID: 17643361] - Frank Dieterle, Götz Schlotterbeck, Martin Binder, Alfred Ross, Laura Suter, Hans Senn. Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates.
Chemical research in toxicology.
2007 Sep; 20(9):1291-9. doi:
10.1021/tx700151t. [PMID: 17676813] - Raoul Bergner, Dirk M Henrich, Martin Hoffmann, Andrea Honecker, Gerd Mikus, Bettina Nauth, Dietmar Nagel, Michael Uppenkamp. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function.
Journal of clinical pharmacology.
2007 Aug; 47(8):942-50. doi:
10.1177/0091270007301801. [PMID: 17615253] - J-J Body, M Lichinitser, S Tjulandin, P Garnero, B Bergström. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Annals of oncology : official journal of the European Society for Medical Oncology.
2007 Jul; 18(7):1165-71. doi:
10.1093/annonc/mdm119. [PMID: 17442659] - C C Glüer, K E Scholz-Ahrens, A Helfenstein, G Delling, W Timm, Y Açil, R Barkmann, J Hassenpflug, B Stampa, F Bauss, J Schrezenmeir. Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs.
Bone.
2007 Mar; 40(3):645-55. doi:
10.1016/j.bone.2006.10.019. [PMID: 17174621] - G Pillai, R Gieschke, T Goggin, J Barrett, E Worth, J L Steimer. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
International journal of clinical pharmacology and therapeutics.
2006 Dec; 44(12):655-67. doi:
10.5414/cpp44655. [PMID: 17190376] - P A Price, A M Roublick, M K Williamson. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate.
Kidney international.
2006 Nov; 70(9):1577-83. doi:
10.1038/sj.ki.5001841. [PMID: 16955099] - V Persy, M De Broe, M Ketteler. Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?.
Kidney international.
2006 Nov; 70(9):1537-8. doi:
10.1038/sj.ki.5001899. [PMID: 17051257] - Eugene Daphnis, Kostas Stylianou, Irene Katsipi, Spyros Stratigis, Eva Karamitopoulou, Nikolaos Karkavitsas, John Kyriazis. Parathyromatosis and the challenge of treatment.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2006 Sep; 48(3):502-5. doi:
10.1053/j.ajkd.2006.05.010. [PMID: 16931226] - J J Body, I J Diel, D Tripathy, B Bergstrom. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.
European journal of cancer care.
2006 Jul; 15(3):299-302. doi:
10.1111/j.1365-2354.2005.00641.x. [PMID: 16882128] - Maria Kiagia, Eleni Karapanagiotou, Adriani Charpidou, Kalliopi Dilana, Georgios Dionellis, Ioannis Dannos, Evangellos Georgiou, Konstantinos N Syrigos. Rapid infusion of ibandronate in lung cancer patients with bone metastases.
Anticancer research.
2006 Jul; 26(4B):3133-6. doi:
NULL. [PMID: 16886646]